Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) released its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13, Zacks reports. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Janux Therapeutics Trading Down 1.8 %

Shares of NASDAQ JANX traded down $0.59 during trading hours on Thursday, hitting $32.01. 425,109 shares of the company traded hands, compared to its average volume of 1,026,279. The company’s 50 day moving average price is $44.72 and its 200 day moving average price is $47.95. Janux Therapeutics has a 12 month low of $31.69 and a 12 month high of $71.71. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -27.36 and a beta of 3.16.

Wall Street Analyst Weigh In

JANX has been the topic of a number of research reports. Leerink Partners lifted their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. HC Wainwright raised their price target on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Finally, Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $89.90.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer now directly owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,668 shares of company stock worth $3,582,515 over the last three months. 29.40% of the stock is owned by insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.